Takeshi Goto

Takeshi Goto

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
TNToshiaki Nakano
Toshiaki Nakano
KCKuei-Chen Chiang
Kuei-Chen Chiang
CCChien-Chih Chen
Chien-Chih Chen
PCPo-Jung Chen
Po-Jung Chen
CLChia-Yun Lai
Chia-Yun Lai
SGShigeru Goto
Shigeru Goto
Most humans depend on sunlight exposure to satisfy their requirements for vitamin D3. However, the destruction of the ozone layer in the past few decades has increased the risk of skin aging and wrinkling caused by excessive exposure to ultraviolet (UV) radiation, which may also promote the risk of skin cancer development. The promotion of public health recommendations to avoid sunlight exposure would reduce the risk of skin cancer, but it would also enhance the risk of vitamin D3 insufficiency/deficiency, which may cause disease development and progression. In addition, the ongoing global COVID-19 pandemic may further reduce sunlight exposure due to stay-at-home policies, resulting in difficulty in active and healthy aging. In this review article, we performed a literature search in PubMed and provided an overview of basic and clinical data regarding the impact of sunlight exposure and vitamin D3 on public health. We also discuss the potential mechanisms and clinical value of phototherapy with a full-spectrum light (notably blue, red, and near-infrared light) as an alternative to sunlight exposure, which may contribute to combating COVID-19 and promoting active and healthy aging in current aged/superaged societies.

1 March 1998 in Analytical Biochemistry
Verified
Journal Article
Closed access
YOYumi Okada
Yumi Okada
KYKoichi Yokono
Koichi Yokono
AKAtsumi Katsuta
Atsumi Katsuta
MYMasaki Yoshida
Masaki Yoshida
SMSumiharu Morita
Sumiharu Morita
KSKozui Shii
Kozui Shii

1 June 2011 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
KCKuei-Chen Chiang
Kuei-Chen Chiang
NONaoya Ohmori
Naoya Ohmori
TGTakeshi Goto
Takeshi Goto
Organ transplantation has become a major therapeutic option for patients with irreversible organ diseases. Immunosuppressive agents are usually required to prevent allograft rejection in patients who undergo an organ transplantation. Such drugs suppress both specific and nonspecific immunity, and render the recipient more susceptible to both infection and malignancy. Therefore, the development of more effective and less toxic immunosuppressive agents could improve the clinical outcomes of organ transplant recipients. Since the early days of clinical and experimental liver transplantation, it has been known that the liver is less likely to be rejected in comparison to other organs and may be tolerogenic even across a fully allogeneic MHC barrier in some specific cases. Spontaneous acceptance of liver allografts has been observed in several species. Orthotopic liver transplantation (OLT) in certain rat strains is accepted without immunosuppressive agents and serum from post-OLT recipients displays immunosuppressive activity. Attempts have been made to identify the immunosuppressive factors that are present in post-OLT serum to elucidate the mechanism of immunolo- gical tolerance and to discover novel immunosuppressive agents for potential use in organ transplantation. In this review we will focus on established and recent findings in the identification of immunosuppressive factors in a rat tolerogenic OLT model. The most recent therapeutic methods in organ transplantation and future prospects will be discussed.